Core Viewpoint - The blood products sector is experiencing revenue growth among listed companies, but profitability is declining due to price reductions driven by increased competition and centralized procurement policies [1][2]. Group 1: Company Performance - In 2024, all nine listed companies in the blood products sector achieved revenue growth, with seven companies reporting an increase in net profit [1]. - In Q1 2024, eight companies reported a decline in net profit year-on-year, including Shanghai Raist and Tian Tan Biological, with declines of 25.20% and 22.90% respectively [1][2]. - Tian Tan Biological attributed its profit decline to a greater reduction in product prices than the increase in sales volume, primarily due to intensified market competition and centralized procurement [2][5]. - Shanghai Raist's net profit decline was also linked to increased credit impairment losses, which surged by 481% due to a rise in accounts receivable [2]. Group 2: Market Dynamics - The price of human albumin has been decreasing, with terminal prices dropping by 10% and 20% for human albumin and intravenous immunoglobulin respectively in Q1 2024 [5]. - The blood products market is characterized by a limited number of qualified players, with fewer than 30 companies holding production qualifications [1]. - The industry is facing pressure from imported human albumin, which is expected to account for 68% of total batch issuance in 2024, creating competitive challenges for domestic producers [7][12]. Group 3: Industry Trends - Centralized procurement has been a significant factor in price reductions, but its impact is considered manageable due to the rigid clinical demand for blood products [6]. - The blood products industry is heavily reliant on plasma supply, with a noted shortage in domestic plasma availability to meet market demand [7][12]. - Companies are actively pursuing acquisitions of plasma collection stations to secure raw material supply, indicating a competitive landscape for plasma resources [14][15].

Core Insights - The Chinese biotechnology industry, focusing on biopharmaceuticals, biomanufacturing, and bioagriculture, is experiencing high-quality development supported by national policies, with a projected industry scale of 21.4 trillion yuan in 2024, representing a year-on-year growth of 3.88% [1][8] - Technological innovation is identified as the core engine for industry advancement, with significant breakthroughs in gene editing, synthetic biology, and cell therapy, enhancing China's competitive position in the global biotechnology landscape [1][8] Industry Overview - The biotechnology sector encompasses living organisms and is classified based on similarities in morphology and physiology, aiding in understanding evolutionary relationships [2] - The industry has evolved through five stages, from initial laboratory research in the 1980s to a focus on commercialization and internationalization in recent years [3][4][5] Market Scale - The biopharmaceutical sector is projected to face pricing pressures, with the PPI index for biopharmaceutical manufacturing at 95.7, down 4.3% year-on-year as of March 2025, yet the demand for biopharmaceuticals is expected to grow due to aging populations and increased health awareness [10] - The biomass power generation capacity in China is expected to reach 45.99 million kilowatts by 2024, with a year-on-year growth of 4.19%, indicating a significant role in the low-carbon energy transition [12] Key Enterprises - Major players in the biopharmaceutical sector include Huazhong Biotech, which has a comprehensive blood product portfolio and a significant vaccine production platform, and Longping High-Tech, known for its hybrid rice innovations and international breeding initiatives [18][20] - The biomanufacturing and bioenergy sectors are led by companies like Guoneng Bio and Malu Bio, focusing on biomass power generation and organic waste treatment, respectively [15][16] Industry Development Trends - Technological innovation is driving breakthroughs across multiple fields, including personalized medicine in biopharmaceuticals and enhanced efficiency in bioenergy production [22][23] - The integration of biomanufacturing and bioagriculture is expected to yield innovative solutions, improving resource utilization and creating a circular economy [25]

Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 867.61 million yuan, a year-on-year increase of 10.2% [3] - Net profit attributable to shareholders was 313.14 million yuan, up 19.62% compared to the same period last year [3] - Net profit excluding non-recurring gains and losses decreased by 35.35% to 299.74 million yuan [3] Group 2: Market Dynamics - The supply of blood products in China is relatively insufficient compared to Europe and the US, indicating significant growth potential in the domestic market [3] - The import volume of human albumin is expected to account for 68% of total approvals in 2024, creating competitive pressure on domestic products [3] - The company’s main product prices remained stable in Q1 2025 compared to the previous year [3] Group 3: Product Development - The company has begun generating sales revenue from Bevacizumab since Q1 2025, following its registration in late 2024 [4] - Several new products are expected to be launched in the next 1-3 years, including Rituximab, which is currently under review [4] Group 4: Operational Efficiency - The company plans to enhance operational efficiency through improved management, increased investment in information technology, and a focus on quality management [4] - In 2024, the company aims to increase plasma collection by enhancing recruitment efforts and upgrading management systems [6] Group 5: Dividend Policy - The company has distributed a total of 5.34 billion yuan in dividends since its listing, with a payout ratio of 30% of net profit planned for 2024-2026 [5] - The dividend amount is 8.52 times the financing amount of 626 million yuan [5] Group 6: Industry Trends - The blood products industry is experiencing consolidation, with the top five companies holding 80%-85% of the market share globally [6] - The company is open to participating in mergers and acquisitions if suitable opportunities arise [6] Group 7: Vaccine Market Strategy - The company plans to adjust the price of its quadrivalent influenza vaccine to enhance market competitiveness [6] - Despite a decline in overall vaccine industry revenue, the company maintains the highest market share and vaccination rates [6]

Investment Rating - The report maintains a "Buy" rating for the company [5][8]. Core Views - The company demonstrated resilience with revenue and profit growth in Q1 2025 despite challenges in the blood products industry, with revenue, net profit attributable to the parent, and net profit excluding non-recurring items increasing by 10.2%, 19.6%, and 35.4% year-over-year, respectively [1]. - The company is expected to benefit from increased plasma collection and recovery in vaccine sales, leading to double-digit revenue growth in 2025 [2][5]. Summary by Sections Financial Performance - In Q1 2025, the company reported revenues of 8.7 billion RMB, net profit attributable to the parent of 3.1 billion RMB, and net profit excluding non-recurring items of 3.0 billion RMB, reflecting year-over-year increases of 10.2%, 19.6%, and 35.4% respectively [1]. - The blood products segment saw revenue growth, with albumin revenue exceeding 3 billion RMB and immunoglobulin revenue surpassing 2 billion RMB [2]. Growth Drivers - The company’s plasma collection volume is projected to grow by 16% in 2025, supported by the addition of new plasma collection stations [2]. - Vaccine sales are expected to recover in 2025 as the market normalizes and competition stabilizes, following a seasonal decline in Q1 2025 [2]. Product Pipeline - The company has several products in development, including high-concentration immunoglobulin and various vaccines, with significant progress in clinical trials [4]. - The approval of biosimilars such as Bevacizumab and Rituximab is anticipated to contribute to revenue growth in the coming years [3]. Valuation and Forecast - The report projects net profits for 2025, 2026, and 2027 to be 13.7 billion RMB, 17.1 billion RMB, and 20.5 billion RMB respectively, with a target price set at 19.40 RMB based on a 26x PE ratio for 2025 [5][9].

Summary of Hualan Biological's Conference Call Company Overview - **Company**: Hualan Biological - **Industry**: Biological Products, Blood Products, Vaccines Key Financial Performance - **2024 Total Revenue**: 2.09 billion CNY, down 18.79% YoY - **2024 Net Profit**: 1.088 billion CNY, down 26.57% YoY - **Q1 2025 Revenue**: 868 million CNY, up 10.2% YoY - **Q1 2025 Net Profit**: 313 million CNY, up 19.62% YoY, indicating signs of recovery [1][2][27] Revenue Breakdown - **Blood Products Revenue (2024)**: 3.25 billion CNY, up 10.9 million CNY YoY - **Vaccine Revenue (2024)**: 1.128 billion CNY, down 53.21% YoY - **Q1 2025 Blood Products Revenue**: 813 million CNY, up 11.98% YoY - **Q1 2025 Vaccine Revenue**: 24 million CNY, down 29.05% YoY [2][8] Plasma Collection and Industry Position - **2024 Plasma Collection**: 1,586 tons, up 18.18% YoY, exceeding industry average growth of 10% - **New Plasma Stations**: Expansion through existing and new stations, with plans for more in traditional regions like Henan and Chongqing [1][5][22] Product Pricing and Inventory - **Price Trends**: Human albumin prices decreased from 420 CNY to 360-380 CNY; immunoglobulin prices dropped from 700 CNY to 550-560 CNY - **Inventory Levels**: Company maintains reasonable inventory levels, with a smaller increase compared to industry peers [6][7][23] New Product Developments - **Biosimilar Sales**: Expected to exceed 100 million CNY in 2025, with a dedicated sales team established - **Upcoming Products**: Bevacizumab launched, with Rituximab application submitted; 1-3 new products expected in the next three years [1][9][10] Market Outlook - **Vaccination Rates**: Optimistic about flu vaccine uptake, anticipating significant growth in sales and profits [1][27] - **Future Growth**: Anticipated annual plasma collection growth of 10%, driven by aging population and demand [20] Strategic Initiatives - **New Factory**: Expected to start production in 2026, with minimal financial pressure from depreciation [3][17] - **Sales Strategy**: Focus on maintaining stable pricing and leveraging brand quality to sustain market position [19][23] Conclusion - **Overall Growth Expectation**: Hualan Biological is positioned for recovery and growth across blood products, vaccines, and monoclonal antibodies, with a collaborative approach to enhance overall performance [28]

Core Viewpoint - The blood products industry is experiencing a significant divergence in performance among companies, with some reporting growth while others face declines in revenue and profit [1][2]. Group 1: Company Performance in 2024 - Shanghai Laisai (002252) and Tiantan Biological (600161) reported revenue growth of 2.67% and 16.44% respectively, with net profits increasing by 23.25% and 39.58% [1]. - Hualan Biological (002007), Boya Biological (300294), and Bohui Innovation (300318) experienced revenue declines of 18.02%, 34.58%, and 18.53% respectively, while Hualan's net profit fell by 26.57% [1]. - Bohui Innovation managed to turn a profit with a net profit of 0.09 billion yuan, compared to a loss in the previous year [1]. Group 2: Q1 2025 Performance - In Q1 2025, Tiantan Biological, Hualan Biological, and Boya Biological continued to show revenue growth, while Shanghai Laisai, Tiantan Biological, and Paillin Biological saw revenue declines of 2.45%, 0.57%, and 14% respectively [1]. - Hualan Biological's net profit increased by 19.62%, while Shanghai Laisai and Tiantan Biological reported net profit declines of 25.2% and 22.9% respectively [1]. - The decline in profits for Tiantan Biological was attributed to a decrease in product prices that outweighed the benefits of increased sales volume [1]. Group 3: Market Dynamics - The blood products market is expected to maintain stable growth in 2024, with significant competition in the human albumin market due to increased imports [2][3]. - The cancellation of certain medical insurance restrictions is expected to release market demand for coagulation factor products, contributing to their growth [2]. - The overall price trend for blood products is declining, influenced by increased competition and supply exceeding demand for certain products [3]. Group 4: Industry Consolidation - The blood products industry is characterized by high entry barriers, with fewer than 30 companies currently operating due to strict regulations on blood product production [6][7]. - Recent mergers and acquisitions are expected to enhance industry concentration, with leading companies gaining competitive advantages through resource acquisition [6][7]. - Companies like Tiantan Biological and Shanghai Laisai have made significant acquisitions to expand their production capabilities and market presence [7]. Group 5: Market Size and Growth Projections - The blood products market in China reached a scale of 600 billion yuan in 2024, with projections to grow to 780 billion yuan by 2027, reflecting a compound annual growth rate of 11.6% from 2022 to 2027 [8].

Core Viewpoint - The company, Hualan Biological Engineering Inc., has released its first quarter report for 2025, ensuring the accuracy and completeness of the financial information disclosed, with no significant omissions or misleading statements [1][2]. Financial Data Summary - The first quarter report has not been audited [3][7]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - Non-recurring gains and losses include a refund of handling fees [3]. - The company confirms that there are no instances of classifying non-recurring gains and losses as recurring [3]. Shareholder Information - As of the reporting period, the total number of ordinary shareholders is not disclosed, but the company holds 6,027,467 shares in a repurchase account, representing 1.00% of total shares, ranking fifth among the top ten shareholders [5].

Group 1: Company Performance - In Q1, Hualan Biological achieved revenue of 868 million yuan, a year-on-year increase of 10.2% [1] - The net profit attributable to shareholders was 313 million yuan, up 19.62% year-on-year, while the net profit excluding non-recurring gains and losses was 300 million yuan, increasing by 35.35% [1] - The blood products segment generated revenue of 843 million yuan, with a year-on-year growth of 11.98% and a net profit of 291 million yuan, reflecting a 23.47% increase [1] Group 2: Vaccine Business - Hualan Vaccine reported Q1 revenue of 24.28 million yuan, a decline of 29.05% year-on-year, with a net profit of 32.78 million yuan, down 15.06% [2] - The net profit excluding non-recurring gains and losses was 15.42 million yuan, showing an increase of 8.89% [2] - The company anticipates that vaccine sales will improve in Q2 as product approvals and sales efforts ramp up [2] Group 3: Industry Trends - The plasma collection volume for Hualan Biological reached a record high of 1586.37 tons in 2024, marking an 18.18% increase [3] - The blood products industry is experiencing increased merger and acquisition activities, with plasma stations becoming a strategic focus for companies [3] - Notable acquisitions include Boya Biological's purchase of 100% of Green Cross China for 1.82 billion yuan, adding 4 plasma stations, and Tian Tan Biological's acquisition of 5 plasma stations from CSL Asia Pacific [3]

Core Viewpoint - Hualan Biological's Q1 2025 financial report shows strong growth driven by its "blood products + vaccines + recombinant protein drugs" strategy, with significant increases in revenue and net profit compared to the previous year [1][2]. Financial Performance - The company achieved a revenue of 868 million yuan, a year-on-year increase of 10.2% [1]. - The net profit attributable to shareholders was 313 million yuan, reflecting a growth of 19.62% year-on-year [1]. - The non-recurring net profit reached 300 million yuan, up 35.35% from the same period last year [1]. - Blood products business generated revenue of 843 million yuan, a growth of 11.98% year-on-year, with a net profit of 291 million yuan, increasing by 23.47% [1]. Product Performance - Hualan Biological maintains a leading market share in domestic blood products, with core product batch approvals remaining among the top in the industry [2]. - The vaccine segment is expected to see growth in Q2 as flu vaccine sales ramp up following seasonal factors [2]. - The new product Bevacizumab began sales in Q1 2025, with expectations for increased sales in Q2, potentially creating a new growth driver [2]. Research and Development - The company invested 66.46 million yuan in R&D, accounting for 7.66% of its revenue, indicating a commitment to biopharmaceutical innovation [2]. - Hualan Biological's plasma collection efforts have led to a record high collection volume of 1586.37 tons in 2024, an increase of 18.18% year-on-year [2]. Strategic Outlook - The Q1 performance validates the effectiveness of the company's three-pronged strategy and demonstrates resilience and robust growth in core business areas [2]. - Future growth is anticipated as domestic vaccine demand recovers and the blood products industry consolidates, with Bevacizumab expected to capture a larger market share in a market projected to reach hundreds of billions [2].

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1.本次股东大会未出现否决议案的情形。 登录新浪财经APP 搜索【信披】查看更多考评等级 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、本次股东大会的召开时间： 现场会议召开时间为：2025年4月25日下午13:00 网络投票时间：2025年4月25日。其中通过深圳证券交易所交易系统进行网络投票的具体时间为2025年4 月25日上午9:15一9:25,9:30一11:30和下午13:00一15:00；通过深圳证券交易所互联网投票的具体时间为 2025年4月25日9:15至15:00期间的任意时间。 2、会议召开地点：华兰生物疫苗股份有限公司（以下简称"公司"）办公楼会议室 3、召集人：公司董事会 4、会议方式：现场投票、网络投票相结合的方式 5、现场会议主持人：董事长安康先生 6、本次股东大会的会议召集、召开程序符合有关法律、法规、规范性文件及《公司章程》的有关规 定。 7、会议出席情况： 公司有表决权股份总数为595,000,033股。 股东出席的总体情况： 通过 ...